NeoGenomics, Inc. (NGNM.OB) Announces Promotions

FT. MYERS, Fla., April 23, 2015 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, announced today several promotions within the company's senior management team.

Douglas VanOort, the Company's Chairman and CEO, commented, "We are very pleased to announce three very well-deserved promotions that were just approved by our Board of Directors. These colleagues have contributed significantly to the Company and their promotions reflect our confidence in their continued ability to deliver the highest quality services to our external and internal customers."

Sally Agersborg, M.D., Ph.D., Director of Hematopathology and Medical Director, Irvine

Dr. Agersborg joined NeoGenomics in 2011 as a Hematopathologist and currently serves as Medical Director, Irvine. Prior to joining NeoGenomics, Dr. Agersborg worked as a Hematopathologist at Quest Diagnostics Nichols Institute. She received her B.S. degree and M.S. degrees from Stanford, earned a combined M.D. in Medicine and Ph.D. in Microbiology from the University of Virginia, and completed her post-graduate medical training in Anatomic Pathology at the University of California, San Francisco.

Jennifer Balliet, Vice President of Human Resources

Jennifer joined NeoGenomics in 2008 and has steadily increased her responsibilities and importance to our company and currently serves as Director of HR. She received her B.S. degree in Psychology and M.S. degree in Business Management from the University of Florida. During her time at NeoGenomics, she has managed the Human Resource process as the company has grown from about 100 employees to about 450 employees. Under her leadership, the company's employee retention rate has climbed from about 60% to about 90%.

Steven Brodie, Ph.D., Chief Scientific Officer and Medical Director, Fort Myers

Dr. Brodie joined NeoGenomics in 2011 as Director of Cytogenetics in Fort Myers and currently serves as Director of Molecular Genetics and Cytogenetics, Florida. Prior to joining NeoGenomics, he served as Senior Director of Cytogenetics, and Assistant Director of Molecular Genetics at Specialty Laboratories/Quest Diagnostics in Valencia CA. He has held various research and clinical positions at the NIH, University of New Mexico school of Medicine, and UCLA David Geffen school of Medicine. Dr. Brodie received in Ph.D. from the UNM School of Medicine and clinical genetics training at the UCLA/Cedars Sinai Medical Center. He is Board certified by the American Board of Medical Genetics.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIAcertified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. For additional information about NeoGenomics, visit

Interested parties can also access investor relations material from Hawk Associates at or [email protected] and from Zack's Investment Research at or [email protected]

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.

To view the original version on PR Newswire, visit:

SOURCE NeoGenomics, Inc.